Почетна › Hronična limfocitna leukemija › Тенеси
Kliničke studije za Hronična limfocitna leukemija u državi Тенеси
16 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u državi Тенеси.
Gradovi u državi Тенеси
Zvanični tekst studije (na engleskom)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
Тражи се учесникОпсервациона студија
Узраст од 12 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07145411Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Тражи се учесникФаза 3
Узраст 65 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07321652Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07520006A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07221500Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06943872A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 31. 8. 2026. · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT05254743The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Тражи се учесникФаза 1/2
Узраст од 12 до 95 · Оба пола · Ажурирано 15. 4. 2026. · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 3. 2026. · NCT04830137A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876662Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.